Table 1.
Baseline characteristics of study participants
| Healthy controls (n=17) | Patients on methotrexate (n=17) | Patients on TNF inhibitors (n=27) | Patients on IL-17 inhibitors (n=15) | Patients on IL-23 inhibitors (n=25) | Total (n=101) | p value | ||
|---|---|---|---|---|---|---|---|---|
| Age, years | 34·0 (27·0–46·0) | 48·0 (41·0–56·0) | 36·0 (28·0–52·0) | 45·0 (38·0–49·0) | 50·0 (33·0–56·0) | 43·0 (31·0–52·0) | 0·053* | |
| Sex | .. | .. | .. | .. | .. | .. | 0·84† | |
| Male | 9 (53%) | 11 (65%) | 13 (48%) | 8 (53%) | 15 (60%) | 56 (55%) | .. | |
| Female | 8 (47%) | 6 (35%) | 14 (52%) | 7 (47%) | 10 (40%) | 45 (45%) | .. | |
| Body-mass index, kg/m2 | 23·0 (21·5–30·5) | 27·1 (26·4–29·7) | 31·2 (26·2–39·4) | 27·6 (25·1–30·9) | 28·7 (27·0–33·1) | 28·2 (25·1–32·7) | 0·032* | |
| Ethnicity | .. | .. | .. | .. | .. | .. | 0·72* | |
| White | 14 (82%) | 13 (76%) | 24 (89%) | 13 (87%) | 21 (84%) | 85 (84%) | .. | |
| Black | 0 | 1 (6%) | 0 | 0 | 0 | 1 (1%) | .. | |
| South Asian | 3 (18%) | 3 (18%) | 3 (11%) | 2 (13%) | 3 (12%) | 14 (14%) | .. | |
| Mixed | 0 | 0 | 0 | 0 | 1 (4%) | 1 (1%) | .. | |
| Disease severity measure (Psoriasis Area Severity Index13) | .. | 2·2 (1·3–3·5) | 1·1 (0·6–2) | 0·6 (0–1·8) | 1·2 (0–2·8) | 1·2 (0·6–2·8)‡ | 0·11† | |
| Concomitant psoriatic arthritis | .. | 2 (12%) | 5 (19%) | 8 (53%) | 5 (20%) | 20/84 (24%) | 0·027* | |
Data are median (IQR), n (%), or n/N (%) unless otherwise specified. Statistical imbalance of the baseline characteristics across the treatment groups is presented by either the Kruskal-Wallis or χ2 test. IL=interleukin. TNF=tumour necrosis factor.
*
χ2 test.
†
Kruskal-Wallis test.
‡
Median for the 84 patients with psoriasis.